FDC Ltd.

₹342.8

1.2 (0.4%)

FDC Share Price

Pharmaceuticals & Biotechnology

As on September 4, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 5,581 Cr

P/E Ratio20.92

Dividend Yield1.46 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	339.16	Bullish
10-DMA	341.74	Bullish
20-DMA	347.73	Bearish
50-DMA	388.08	Bearish
100-DMA	383.64	Bearish
200-DMA	383.67	Bearish

Historical Performance

1 Year

-25.5%

3 Years

-9.5%

5 Years

0.7%

10 Years

75.2%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	21,081	19,429	17,838	15,279	13,332
Total Expenditure	17,833	16,044	15,342	12,742	9,991
Other Income	907	1,016	512	761	970
Operating Profit	4,155	4,402	3,008	3,298	4,311
Interest	45	40	41	31	34
Depreciation	537	399	389	373	378
Profit Before Tax	3,572	3,962	2,578	2,894	3,877
Consolidated Net Profit	2,668	3,051	1,940	2,164	3,013
Adjusted EPS	16	19	12	13	18

Compounded Sales Growth

10 Years:18.8

5 Years:9.4

3 Years:6.6

TTM:1.6

Compounded Profit Growth

10 Years:12.5

5 Years:2.1

3 Years:4.3

TTM:-2.6

Stock Price CAGR

10 Years:5.5

5 Years:0

3 Years:-3.8

TTM:-27.2

Return on Equity

10 Years:9.5

5 Years:17.9

3 Years:11.7

last year:16.4

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	163	163	166	169	169
Total Reserves	22,648	20,809	19,655	19,399	17,172
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	8,119	6,042	4,686	3,912	2,996
Other Current Liabilities	1,246	1,015	966	864	774
Short Term Borrowings	---	---	---	---	---
Total Liabilities	36,433	33,165	31,796	30,379	26,554
Capital Work in Progress	1,361	2,609	1,977	1,047	192
Long Term Loans & Advances	8,332	6,095	4,874	4,241	3,287
Currents Investments	4,847	4,500	4,573	5,008	5,248
Short Term Loans and Advances	2,416	3,653	4,997	4,804	4,504
Total Current Assets	12,740	13,670	14,431	14,184	13,479
Total Assets	36,433	33,165	31,796	30,379	26,554
Adjusted Book Value	140	129	119	116	103

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 20.92, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a weak 3-year price CAGR of -3.8%, indicating poor shareholder returns.
The stock carries a low beta of 0.5, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹4155 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹21081 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 735306.7

No. of Shares: 2145 (Approx)

Performance:-26.5%

-264693.3

NIFTY Performance: -3.4%

1 day Top Gainers